|
1
|
Biasatti A, Bignante G, Ditonno F, Veccia
A, Bertolo R, Antonelli A, Lee R, Eun DD, Margulis V, Abdollah F,
et al: New insights into upper tract urothelial carcinoma: Lessons
learned from the ROBUUST collaborative study. Cancers (Basel).
17:16682025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nally E, Young M, Chauhan V, Wells C,
Szabados B, Powles T and Jackson-Spence F: Upper tract urothelial
carcinoma (UTUC): Prevalence, impact and management challenge.
Cancer Manag Res. 16:467–475. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jubber I, Ong S, Bukavina L, Black PC,
Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks
JJ, et al: Epidemiology of Bladder Cancer in 2023: A Systematic
Review of Risk Factors. Eur Urol. 84:176–190. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moussa MJ, Campbell MT and Alhalabi O:
Revisiting treatment of metastatic urothelial cancer: Where do
cisplatin and platinum ineligibility criteria stand? Biomedicines.
12:5192024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rivera C, Jabbal IS, Yaghi M, Landau KS,
Muruve N, Saravia D, George TL, Nahleh ZA and Arteta-Bulos R:
Five-year survival comparison of different treatment modalities for
muscle invasive urothelial carcinoma, squamous cell carcinoma and
adenocarcinoma of the bladder: An analysis of the National cancer
database. J Clin Oncol. 40(6_suppl): S5752022. View Article : Google Scholar
|
|
6
|
Gupta S, Andreev-Drakhlin A, Fajardo O,
Fassò M, Garcia JA, Wee C and Schröder C: Platinum ineligibility
and survival outcomes in patients with advanced urothelial
carcinoma receiving first-line treatment. J Natl Cancer Inst.
116:547–554. 2024. View Article : Google Scholar
|
|
7
|
Mao L, Yang M, Fan X, Li W, Huang X, He W,
Lin T and Huang J: PD-1/L1 inhibitors can improve but not replace
chemotherapy for advanced urothelial carcinoma: A systematic review
and network meta-analysis. Cancer Innov. 2:191–202. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li XK and Wang WL: The role novel targeted
agents in the treatment of previously treated patients with
advanced urothelial carcinoma (UC): A meta-analysis. Eur Rev Med
Pharmacol Sci. 22:5165–5171. 2018.PubMed/NCBI
|
|
9
|
Siefker-Radtke AO, Necchi A, Park SH,
García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh
Kalebasty A, Mellado B, Varlamov S, et al: Efficacy and safety of
erdafitinib in patients with locally advanced or metastatic
urothelial carcinoma: Long-term follow-up of a phase 2 study.
Lancet Oncol. 23:248–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu EY, Petrylak DP, O'Donnell PH, Lee JL,
van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T,
Harrison MR, et al: Enfortumab vedotin after PD-1 or PD-L1
inhibitors in cisplatin-ineligible patients with advanced
urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2
trial. Lancet Oncol. 22:872–882. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seront E and Machiels JP: Molecular
biology and targeted therapies for urothelial carcinoma. Cancer
Treat Rev. 41:341–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glaser AP, Fantini D, Shilatifard A,
Schaeffer EM and Meeks JJ: The evolving genomic landscape of
urothelial carcinoma. Nat Rev Urol. 14:215–229. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ching CB and Hansel DE: Expanding
therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway.
Lab Invest. 90:1406–1414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He F, Zhang F, Liao Y, Tang MS and Wu XR:
Structural or functional defects of PTEN in urothelial cells
lacking P53 drive basal/squamous-subtype muscle-invasive bladder
cancer. Cancer Lett. 550:2159242022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patel VG, McBride RB, Lorduy AC,
Castillo-Martin M, Cha EK, Berger MF, Wang L, Oh WK, Zhu J,
Cordon-Cardo C, et al: Prognostic significance of PIK3CA mutation
in patients with muscle-invasive urothelial carcinoma (UC). J Clin
Oncol. 34(15_suppl): e160022016. View Article : Google Scholar
|
|
16
|
Wang DS, Rieger-Christ K, Latini JM,
Moinzadeh A, Stoffel J, Pezza JA, Saini K, Libertino JA and
Summerhayes IC: Molecular analysis of PTEN and MXI1 in primary
bladder carcinoma. Int J Cancer. 88:620–625. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuruta H, Kishimoto H, Sasaki T, Horie Y,
Natsui M, Shibata Y, Hamada K, Yajima N, Kawahara K, Sasaki M, et
al: Hyperplasia and carcinomas in Pten-deficient mice and reduced
PTEN protein in human bladder cancer patients. Cancer Res.
66:8389–8396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imperial R, Toor OM, Hussain A,
Subramanian J and Masood A: Comprehensive pancancer genomic
analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in
cancer: Its clinical implications. Semin Cancer Biol. 54:14–28.
2019. View Article : Google Scholar
|
|
19
|
Degirmenci U, Wang M and Hu J: Targeting
aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells.
9:1982020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim YS, Lee SC, Hwang IG, Lee SJ and Park
SH: Relationship between RAS, BRAF, PIK3CA and location of primary
tumor in urothelial carcinoma. Cancer Res. 79(13_Suppl): S12622019.
View Article : Google Scholar
|
|
21
|
Zhou H, Huang HY, Shapiro E, Lepor H,
Huang WC, Mohammadi M, Mohr I, Tang MS, Huang C and Wu XR:
Urothelial tumor initiation requires deregulation of multiple
signaling pathways: implications in target-based therapies.
Carcinogenesis. 33:770–780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu G, Wang F, Li K, Li S, Zhao C, Fan C
and Wang J: Significance of TP53 mutation in bladder cancer disease
progression and drug selection. PeerJ. 7:e82612019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ecke TH, Sachs MD, Lenk SV, Loening SA and
Schlechte HH: TP53 gene mutations as an independent marker for
urinary bladder cancer progression. Int J Mol Med. 21:655–661.
2008.PubMed/NCBI
|
|
24
|
Khalid S, Basulaiman BM, Emack J, Booth
CM, Hernandez-Barajas D, Duran I, Smoragiewicz M, Amir E and
Vera-Badillo F: FGFR3 mutation as a prognostic indicator in
patients with urothelial carcinoma: A systematic review and
meta-analysis. J Clin Oncol. 37(7_suppl): S4112019. View Article : Google Scholar
|
|
25
|
Che X, Liu H, Qin J and Cao S: Landscape
of FGFR2/3 alterations in genitourinary cancer. J Clin Oncol.
41(16_suppl): e150472023. View Article : Google Scholar
|
|
26
|
Liu X, Zhang W, Geng D, He J, Zhao Y and
Yu L: Clinical significance of fibroblast growth factor receptor-3
mutations in bladder cancer: a systematic review and meta-analysis.
Genet Mol Res. 13:1109–1120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeng P, Chen MB, Zhou LN, Tang M, Liu CY
and Lu PH: Impact of TROP2 expression on prognosis in solid tumors:
A Systematic Review and Meta-analysis. Sci Rep. 6:336582016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tagawa ST, Balar AV, Petrylak DP,
Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M,
Barthelemy P, et al: TROPHY-U-01: A phase II open-label study of
sacituzumab govitecan in patients with metastatic urothelial
carcinoma progressing after platinum-based chemotherapy and
checkpoint inhibitors. J Clin Oncol. 39:2474–2485. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosenberg JE, Powles T, Sonpavde GP,
Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D,
Mamtani R, et al: EV-301 long-term outcomes: 24-month findings from
the phase III trial of enfortumab vedotin versus chemotherapy in
patients with previously treated advanced urothelial carcinoma. Ann
Oncol. 34:1047–1054. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tagawa ST, Balar AV, Petrylak DP,
Rezazadeh A, Loriot Y, Flechon A, Jain RK, Agarwal N, Bupathi M,
Barthelemy P, et al: Updated outcomes in TROPHY-U-01 cohort 1, a
phase 2 study of sacituzumab govitecan (SG) in patients (pts) with
metastatic urothelial cancer (mUC) that progressed after platinum
(PT)-based chemotherapy and a checkpoint inhibitor (CPI). J Clin
Oncol. 41(6_suppl): S5262023. View Article : Google Scholar
|
|
31
|
Hall TG, Yu Y, Eathiraj S, Wang Y, Savage
RE, Lapierre JM, Schwartz B and Abbadessa G: Preclinical activity
of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS
One. 11:e01625942016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dienstmann R, Rodon J, Prat A,
Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P
and Tabernero J: Genomic aberrations in the FGFR pathway:
Opportunities for targeted therapies in solid tumors. Ann Oncol.
25:552–563. 2014. View Article : Google Scholar
|
|
33
|
Ross JS, Wang K, Khaira D, Ali SM, Fisher
HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, et al:
Comprehensive genomic profiling of 295 cases of clinically advanced
urothelial carcinoma of the urinary bladder reveals a high
frequency of clinically relevant genomic alterations. Cancer.
122:702–711. 2016. View Article : Google Scholar
|
|
34
|
Kim YS, Kim K, Kwon GY, Lee SJ and Park
SH: Fibroblast growth factor receptor 3 (FGFR3) aberrations in
muscle-invasive urothelial carcinoma. BMC Urol. 18:682018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gamallat Y, Afsharpad M, El Hallani S,
Maher CA, Alimohamed N, Hyndman E and Bismar TA: Large, nested
variant of urothelial carcinoma is enriched with activating
mutations in fibroblast growth factor receptor-3 among other
targetable mutations. Cancers (Basel). 15:31672023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Necchi A, Lo Vullo S, Raggi D, Gloghini A,
Giannatempo P, Colecchia M and Mariani L: Prognostic effect of FGFR
mutations or gene fusions in patients with metastatic urothelial
carcinoma receiving first-line platinum-based chemotherapy: Results
from a large, single-institution cohort. Eur Urol Focus. 5:853–856.
2019. View Article : Google Scholar
|
|
37
|
Huang GK, Huang CC, Kang CH, Cheng YT,
Tsai PC, Kao YH and Chung YH: Genetic Interference of FGFR3 impedes
invasion of upper tract urothelial carcinoma cells by alleviating
RAS/MAPK signal activity. Int J Mol Sci. 24:17762023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Li Y, Liu B, Chen L, Lyu F, Zhang P,
He Q, Cheng L, Liu C, Song Y and Xing Y: P4HA2-mediated HIF-1α
stabilization promotes erdafitinib-resistance in FGFR3-alteration
bladder cancer. FASEB J. 37:e228402023. View Article : Google Scholar
|
|
39
|
Shohdy KS, Vlachostergios PJ, Abdel-Malek
RR and Faltas BM: Rationale for co-targeting CDK4/6 and FGFR
pathways in urothelial carcinoma. Expert Opin Ther Targets.
23:83–86. 2019. View Article : Google Scholar
|
|
40
|
Khalid S, Basulaiman BM, Emack J, Booth
CM, Duran I, Robinson AG, Berman D, Smoragiewicz M, Amir E and
Vera-Badillo FE: Fibroblast growth factor receptor 3 mutation as a
prognostic indicator in patients with urothelial carcinoma: A
systematic review and meta-analysis. Eur Urol Open Sci. 21:61–68.
2020. View Article : Google Scholar
|
|
41
|
Song Y, Peng Y, Qin C, Wang Y, Yang W, Du
Y and Xu T: Fibroblast growth factor receptor 3 mutation attenuates
response to immune checkpoint blockade in metastatic urothelial
carcinoma by driving immunosuppressive microenvironment. J
Immunother Cancer. 11:e0066432023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Okato A, Utsumi T, Ranieri M, Zheng X,
Zhou M, Pereira LD, Chen T, Kita Y, Wu D, Hyun H, et al: FGFR
inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant
bladder cancer by abrogating immunosuppression. J Clin Invest.
134:e1692412024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahmoud SF, Holah NS, Alhanafy AM and
Serag El-Edien MM: Do fibroblast growth factor receptor (FGFR) 2
and 3 proteins play a role in prognosis of invasive urothelial
bladder carcinoma? Iran J Pathol. 19:81–88. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Loriot Y, Necchi A, Park SH, Garcia-Donas
J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B,
Varlamov S, et al: Erdafitinib in locally advanced or metastatic
urothelial carcinoma. N Engl J Med. 381:338–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Parker Kerrigan BC, Ledbetter D, Kronowitz
M, Phillips L, Gumin J, Hossain A, Yang J, Mendt M, Singh S,
Cogdell D, et al: RNAi technology targeting the FGFR3-TACC3 fusion
break-point: An opportunity for precision medicine. Neurooncol Adv.
2:vdaa1322020.
|
|
46
|
Lyou Y, Grivas P, Rosenberg JE,
Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan
U, De Giorgi U, Gupta S, et al: Hyperphosphatemia secondary to the
selective fibroblast growth factor receptor 1-3 inhibitor
infigratinib (BGJ398) is associated with antitumor efficacy in
fibroblast growth factor receptor 3-altered advanced/metastatic
urothelial carcinoma. Eur Urol. 78:916–924. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Loriot Y, Matsubara N, Park SH, Huddart
RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama
BP, et al: Erdafitinib or chemotherapy in advanced or metastatic
urothelial carcinoma. N Engl J Med. 389:1961–1971. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Siefker-Radtke AO, Matsubara N, Park SH,
Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B,
Basso U, Triantos S, et al: Erdafitinib versus pembrolizumab in
pretreated patients with advanced or metastatic urothelial cancer
with select FGFR alterations: cohort 2 of the randomized phase III
THOR trial. Ann Oncol. 35:107–117. 2024. View Article : Google Scholar
|
|
49
|
Guercio BJ, Sarfaty M, Teo MY, Ratna N,
Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, et al:
Clinical and genomic landscape of FGFR3-altered urothelial
carcinoma and treatment outcomes with erdafitinib: A real-world
experience. Clin Cancer Res. 29:4586–4595. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lyou Y, Rosenberg JE, Hoffman-Censits J,
Quinn DI, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta
S, Burris H, et al: Infigratinib in early-line and salvage therapy
for FGFR3-Altered metastatic urothelial carcinoma. Clin Genitourin
Cancer. 20:35–42. 2022. View Article : Google Scholar :
|
|
51
|
Pal SK, Somford DM, Grivas P, Sridhar SS,
Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y,
et al: Targeting FGFR3 alterations with adjuvant infigratinib in
invasive urothelial carcinoma: The phase III PROOF 302 trial.
Future Oncol. 18:2599–2614. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sternberg CN, Petrylak DP, Bellmunt J,
Nishiyama H, Necchi A, Gurney H, Lee JL, van der Heijden MS,
Rosenbaum E, Penel N, et al: FORT-1: Phase II/III study of
rogaratinib versus chemotherapy in patients with locally advanced
or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA
expression. J Clin Oncol. 41:629–639. 2023. View Article : Google Scholar :
|
|
53
|
Necchi A, Pouessel D, Leibowitz R, Gupta
S, Fléchon A, García-Donas J, Bilen MA, Debruyne PR, Milowsky MI,
Friedlander T, et al: Pemigatinib for metastatic or surgically
unresectable urothelial carcinoma with FGF/FGFR genomic
alterations: Final results from FIGHT-201. Ann Oncol. 35:200–210.
2024. View Article : Google Scholar
|
|
54
|
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell
EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, et al: Phase II
study of erdafitinib in patients with tumors with FGFR
amplifications: results from the NCI-MATCH ECOG-ACRIN trial
(EAY131) subprotocol K1. JCO Precis Oncol. 8:e23004062024.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Siefker-Radtke AO and Loriot Y:
Erdafitinib for locally advanced or metastatic urothelial
carcinoma. Am J Health Syst Pharm. 79:824–825. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Necchi A, Ramlau R, Falcón González A,
Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P,
Deville JL, Pouessel D, et al: Derazantinib alone and with
atezolizumab in metastatic urothelial carcinoma with activating
FGFR aberrations. JNCI Cancer Spectr. 8:pkae0302024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Datta J, Damodaran S, Parks H, Ocrainiciuc
C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, et
al: Akt activation mediates acquired resistance to fibroblast
growth factor receptor inhibitor BGJ398. Mol Cancer Ther.
16:614–624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pettitt GA, Hurst CD, Khan Z, McPherson
HR, Dunning MC, Alder O, Platt FM, Black EV, Burns JE and Knowles
MA: Development of resistance to FGFR inhibition in urothelial
carcinoma via multiple pathways in vitro. J Pathol. 259:220–232.
2023. View Article : Google Scholar :
|
|
59
|
Kim SH, Ryu H, Ock CY, Suh KJ, Lee JY, Kim
JW, Lee JO, Kim JW, Kim YJ, Lee KW, et al: BGJ398, A Pan-FGFR
inhibitor, overcomes paclitaxel resistance in urothelial carcinoma
with FGFR1 overexpression. Int J Mol Sci. 19:31642018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rezazadeh Kalebasty A, Benjamin DJ, Loriot
Y, Papantoniou D, Siefker-Radtke AO, Necchi A, Naini V, Carcione
JC, Santiago-Walker A, Triantos S and Burgess EF: Outcomes of
patients with advanced urothelial carcinoma after anti-programmed
Death-(ligand) 1 therapy by fibroblast growth factor receptor gene
alteration status: An observational study. Eur Urol Open Sci.
47:48–57. 2022. View Article : Google Scholar
|
|
61
|
Bellmunt J, Lalani AA, Jacobus S,
Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I,
Lundgren K, et al: Everolimus and pazopanib (E/P) benefit
genomically selected patients with metastatic urothelial carcinoma.
Br J Cancer. 119:707–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Brunelli M, Gobbo S, Malpeli G,
Sirgiovanni G, Caserta C, Munari E, Francesconi S, Caliò A,
Martignoni G, Cimadamore A, et al: TROP-2, NECTIN-4 and predictive
biomarkers in sarcomatoid and rhabdoid bladder urothelial
carcinoma. Pathologica. 116:55–61. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Audisio M, Buttigliero C, Turco F,
Delcuratolo MD, Pisano C, Parlagreco E, Di Stefano RF, Di Prima L,
Crespi V, Farinea G, et al: Metastatic urothelial carcinoma: Have
we take the road to the personalized medicine? Cells. 11:16142022.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Heath EI and Rosenberg JE: The biology and
rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev
Urol. 18:93–103. 2021. View Article : Google Scholar
|
|
65
|
Gupta S, Loriot Y, Van der Heijden MS,
Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis
M, Galsky MD, et al: Enfortumab vedotin plus pembrolizumab versus
chemotherapy in patients with previously untreated locally advanced
or metastatic urothelial cancer (EV-302): Patient-reported outcomes
from an open-label, randomised, controlled, phase 3 study. Lancet
Oncol. 26:795–805. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li S, Shi Y, Dong H, Guo H, Xie Y, Sun Z,
Zhang X, Kim E, Zhang J, Li Y, et al: Phase 2 trial of enfortumab
vedotin in patients with previously treated locally advanced or
metastatic urothelial carcinoma in China. Cancer Med.
13:e703682025. View Article : Google Scholar
|
|
67
|
Rizzo M, Morelli F, Ürün Y, Buti S, Park
SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, et
al: Real-life impact of enfortumab vedotin or chemotherapy in the
sequential treatment of advanced urothelial carcinoma: The ARON-2
retrospective experience. Cancer Med. 14:e704792025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Uchimoto T, Iwatsuki K, Komura K,
Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta
M, Hashimoto M, et al: Association of body mass index and tumor
response in metastatic urothelial carcinoma treated with enfortumab
vedotin: data from the ULTRA-Japan consortium. Int J Clin Oncol.
30:761–769. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mishra A, Sharma AK, Gupta K, Banka DR,
Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ and Nimmagadda
S: Nectin-4 Pet for optimizing enfortumab vedotin dose-response in
urothelial carcinoma. bioRxiv [Preprint]. 2024.12.25.630315.
2024.
|
|
70
|
Jindal T, Zhu X, Bose R, Kumar V,
Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis
A, et al: Somatic alterations of TP53 and MDM2 associated with
response to enfortumab vedotin in patients with advanced urothelial
cancer. Front Oncol. 13:11610892023. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hovelroud R, Goh Xiu Ming S, McLeod DSA,
Donovan PJ, Ng G and Mungomery M: A case of enfortumab
vedotin-associated diabetic ketoacidosis with severe insulin
resistance in a nondiabetic woman. JCEM Case Rep. 2:luae2122024.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Desimpel G, Zammit F, Lejeune S, Grisay G
and Seront E: Lung toxicity occurring during enfortumab vedotin
treatment: From a priming case report to a retrospective analysis.
Pharmaceuticals (Basel). 17:15472024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Pipitone S, Vitale MG, Baldessari C,
Sabbatini R, Dominici M, Porretta Serapiglia C, Ricchi L and Rivasi
M: Extravasation of enfortumab vedotin: A case report and
literature review on antibody-drug conjugates. Eur J Hosp
Pharmejhpharm. 2024-0043232025.Epub ahead of print. View Article : Google Scholar
|
|
74
|
Zhu Y, Liu K, Zhu H, Li S and Yuan D:
Enfortumab vedotin plus pembrolizumab for previously untreated
locally advanced or metastatic urothelial carcinoma: A
cost-effectiveness analysis. Ther Adv Med Oncol.
17:175883592412955442025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update.
Arch Pathol Lab Med. 142:1364–1382. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo
H, Shi B, Liu J, He Z, Yu G, et al: Open-label, multicenter, phase
II Study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in
patients with locally advanced or metastatic urothelial carcinoma.
Clin Cancer Res. 27:43–51. 2021. View Article : Google Scholar
|
|
77
|
Sheng X, Wang L, He Z, Shi Y, Luo H, Han
W, Yao X, Shi B, Liu J, Hu C, et al: Efficacy and safety of
disitamab vedotin in patients with human epidermal growth factor
receptor 2-positive locally advanced or metastatic urothelial
carcinoma: A combined analysis of two phase II clinical trials. J
Clin Oncol. 42:1391–1402. 2024. View Article : Google Scholar
|
|
78
|
Chen M, Yao K, Cao M, Liu H, Xue C, Qin T,
Meng L, Zheng Z, Qin Z, Zhou F, et al: HER2-targeting antibody-drug
conjugate RC48 alone or in combination with immunotherapy for
locally advanced or metastatic urothelial carcinoma: A multicenter,
real-world study. Cancer Immunol Immunother. 72:2309–2318. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yan X, Li J, Xu H, Liu Y, Zhou L, Li S, Wu
X, Tang B, Chi Z, Cui C, et al: Efficacy and safety of DV in
HER2-negative and HER2-low locally advanced or metastatic
urothelial carcinoma: Results of a phase 2 study. Med.
6:1006372025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wang D, Cao M, Zhang Y, Bi L, Chen M, Ni
M, Zheng Q, Yao K, Liu Z, Yang X, et al: RC48-ADC monotherapy or in
combination with immunotherapy for locally advanced or metastatic
urothelial carcinoma with HER2 low and null expression: A
multicenter, real-world, retrospective study. BMC Cancer.
25:8122025. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhou L, Yang KW, Zhang S, Yan XQ, Li SM,
Xu HY, Li J, Liu YQ, Tang BX, Chi ZH, et al: Disitamab vedotin plus
toripalimab in patients with locally advanced or metastatic
urothelial carcinoma (RC48-C014): A phase Ib/II dose-escalation and
dose-expansion study. Ann Oncol. 36:331–339. 2025. View Article : Google Scholar
|
|
82
|
Yao JW, Zhong JL, Zhou Q and Guo J:
Efficacy and safety of disitamab vedotin in combination with immune
checkpoint inhibitors in patients with locally advanced or
metastatic urothelial carcinoma. World J Urol. 43:1542025.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ge H, Liu C, Shen C, Hu D, Zhao X and Wang
Y, Ge H, Qin R, Ma X and Wang Y: The effectiveness and safety of
RC48 alone or in combination with PD-1 inhibitors for locally
advanced or metastatic urothelial carcinoma: A multicenter,
real-world study. J Transl Med. 23:2432025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yang M, Yao Y, Wang K, Qi L, Yang B,
Khudadad M, Guo Y, Wang Y, Liu Y, Li L, et al: Clinicopathological
characteristics and prognostic significance of HER2 status
evaluation in patients with urothelial carcinoma: A retrospective
single-center experience in China. Virchows Arch. Feb 26–2025.Epub
ahead of print. View Article : Google Scholar
|
|
85
|
Chen Y, Luo F, Zhang T and Li J: Impact of
HER2 expression on the prognosis of muscle-invasive bladder cancer
patients treated with bladder-preservation comprehensive therapy.
Biol Proced Online. 27:22025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chou J, Trepka K, Sjöström M, Egusa EA,
Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, et al:
TROP2 expression across molecular subtypes of urothelial carcinoma
and enfortumab vedotin-resistant cells. Eur Urol Oncol. 5:714–718.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Bahlinger V, Branz A, Strissel PL, Strick
R, Lange F, Geppert CI, Klümper N, Hölzel M, Wach S, Taubert H, et
al: Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with
molecular subtypes, PD-L1 expression, and FGFR3 mutational status
in two advanced urothelial bladder cancer cohorts. Histopathology.
84:863–876. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Katims AB, Reisz PA, Nogueira L, Truong H,
Lenis AT, Pietzak EJ, Kim K and Coleman JA: Targeted therapies in
advanced and metastatic urothelial carcinoma. Cancers (Basel).
14:54312022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Shvartsbart A, Roach JJ, Witten MR,
Koblish H, Harris JJ, Covington M, Hess R, Lin L, Frascella M,
Truong L, et al: Discovery of potent and selective inhibitors of
wild-type and gatekeeper mutant fibroblast growth factor receptor
(FGFR) 2/3. J Med Chem. 65:15433–15442. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shih CH, Lin YH, Luo HL and Sung WW:
Antibody-drug conjugates targeting HER2 for the treatment of
urothelial carcinoma: Potential therapies for HER2-positive
urothelial carcinoma. Front Pharmacol. 15:13262962024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Khosravanian MJ, Mirzaei Y, Mer AH,
Keyhani-Khankahdani M, Abdinia FS, Misamogooe F, Amirkhani Z,
Bagheri N, Meyfour A, Jahandideh S, et al: Nectin-4-directed
antibody-drug conjugates (ADCs): Spotlight on preclinical and
clinical evidence. Life Sci. 352:1229102024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Chu CE, Sjöström M, Egusa EA, Gibb EA,
Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, et al:
Heterogeneity in NECTIN4 expression across molecular subtypes of
urothelial cancer mediates sensitivity to enfortumab vedotin. Clin
Cancer Res. 27:5123–5130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Guancial EA, Werner L, Bellmunt J, Bamias
A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS,
et al: FGFR3 expression in primary and metastatic urothelial
carcinoma of the bladder. Cancer Med. 3:835–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ross JS, Gay LM, Ferry EK, Jacob J,
Shapiro O, Hoffman-Censits JH, Millis SZ, Elvin JA, Chung J,
Vergilio JA, et al: FGFR3 Driven Metastatic Urothelial Carcinoma of
the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling
Study. J Clin Oncol. 36(15_suppl): 4531. 2018. View Article : Google Scholar
|
|
95
|
Redig AJ, Costa DB, Taibi M, Boucher D,
Johnson BE, Jänne PA and Jackman DM: Prospective study of repeated
biopsy feasibility and acquired resistance at disease progression
in patients with advanced EGFR mutant lung cancer treated with
erlotinib in a phase 2 trial. JAMA Oncol. 2:1240–1242. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kang M and Ku JH: Emerging role of liquid
biopsy of cell-free tumor DNA for bladder cancer surveillance.
Transl Androl Urol. 6:590–592. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bambury RM and Rosenberg JE: Advanced
urothelial carcinoma: Overcoming treatment resistance through novel
treatment approaches. Front Pharmacol. 4:32013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang P, Shi Y, Zhang J, Shou J, Zhang M,
Zou D, Liang Y, Li J, Tan Y, Zhang M, et al: UCseek: Ultrasensitive
early detection and recurrence monitoring of urothelial carcinoma
by shallow-depth genome-wide bisulfite sequencing of urinary
sediment DNA. EBioMedicine. 89:1044372023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Pichler R, van Creij NCH, Subiela JD,
Cimadamore A, Caño-Velasco J, Tully KH, Mori K, Contieri R, Afferi
L, Mari A, et al: Biological and therapeutic implications of FGFR
alterations in urothelial cancer: A systematic review from
non-muscle-invasive to metastatic disease. Actas Urol Esp (Engl
Ed). 49:5017192025.In English, Spanish. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhang R, Zang J, Jin D, Xie F, Shahatiaili
A, Wu G, Zhang L, Wang L, Zhang Y, Zhao Z, et al: Urinary tumor DNA
MRD analysis to identify responders to neoadjuvant immunotherapy in
muscle-invasive bladder cancer. Clin Cancer Res. 29:4040–4046.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Benjamin DJ and Mita AC: FGFR-altered
urothelial carcinoma: Resistance mechanisms and therapeutic
strategies. Target Oncol. 20:1–11. 2025. View Article : Google Scholar
|
|
102
|
Yajima S and Masuda H: Immune checkpoint
inhibitors and antibody-drug conjugates in urothelial carcinoma:
Current landscape and future directions. Cancers (Basel).
17:15942025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Katoh M, Loriot Y, Brandi G, Tavolari S,
Wainberg ZA and Katoh M: FGFR-targeted therapeutics: Clinical
activity, mechanisms of resistance and new directions. Nat Rev Clin
Oncol. 21:312–329. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Khoury R, Saleh K, Khalife N, Saleh M,
Chahine C, Ibrahim R and Lecesne A: Mechanisms of resistance to
antibody-drug conjugates. Int J Mol Sci. 24:96742023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Szklener K, Chmiel P, Michalski A and
Mańdziuk S: New directions and challenges in targeted therapies of
advanced bladder cancer: The role of FGFR inhibitors. Cancers
(Basel). 14:14162022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Khajah MA, Mathew PM and Luqmani YA:
Inhibitors of PI3K/ERK1/2/p38 MAPK Show preferential activity
against endocrine-resistant breast cancer cells. Oncol Res.
25:1283–1295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Feldt SL and Bestvina CM: The role of MET
in resistance to EGFR inhibition in NSCLC: A review of mechanisms
and treatment implications. Cancers (Basel). 15:29982023.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Manzano RG, Catalan-Latorre A and
Brugarolas A: RB1 and TP53 co-mutations correlate strongly with
genomic biomarkers of response to immunity checkpoint inhibitors in
urothelial bladder cancer. BMC Cancer. 21:4322021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ungaro A, Tucci M, Audisio A, Di Prima L,
Pisano C, Turco F, Delcuratolo MD, Di Maio M, Scagliotti GV and
Buttigliero C: Antibody-Drug conjugates in urothelial carcinoma: A
new therapeutic opportunity moves from bench to bedside. Cells.
11:8032022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wise AR, Maloney S, Hering A, Zabala S,
Richmond GE, VanKlompenberg MK, Nair MT and Prosperi JR: Bcl-2
Up-Regulation Mediates Taxane Resistance Downstream of APC Loss.
Int J Mol Sci. 25:67452024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Das C, Adhikari S, Bhattacharya A,
Chakraborty S, Mondal P, Yadav SS, Adhikary S, Hunt CR, Yadav KK,
Pandita S, et al: Epigenetic-metabolic interplay in the DNA damage
response and therapeutic resistance of breast cancer. Cancer Res.
83:657–666. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Klümper N, Ralser DJ, Ellinger J, Roghmann
F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, et
al: Membranous NECTIN-4 expression frequently decreases during
metastatic spread of urothelial carcinoma and is associated with
enfortumab vedotin resistance. Clin Cancer Res. 29:1496–1505. 2023.
View Article : Google Scholar :
|
|
113
|
Qu M, Zhou L, Yan X, Li S, Wu X, Xu H, Li
J, Guo J, Zhang X, Li H and Sheng X: Advances in HER2-Targeted
treatment for advanced/metastatic urothelial carcinoma. Bladder
(San Franc). 10:e212000122023.PubMed/NCBI
|
|
114
|
Watts TL, Cui R, Szaniszlo P, Resto VA,
Powell DW and Pinchuk IV: PDGF-AA mediates mesenchymal stromal cell
chemotaxis to the head and neck squamous cell carcinoma tumor
microenvironment. J Transl Med. 14:3372016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Chen CH, Changou CA, Hsieh TH, Lee YC, Chu
CY, Hsu KC, Wang HC, Lin YC, Lo YN, Liu YR, et al: Dual inhibition
of PIK3C3 and FGFR as a new therapeutic approach to treat bladder
cancer. Clin Cancer Res. 24:1176–1189. 2018. View Article : Google Scholar
|
|
116
|
Hosaka K, Yang Y, Seki T, Du Q, Jing X, He
X, Wu J, Zhang Y, Morikawa H, Nakamura M, et al: Therapeutic
paradigm of dual targeting VEGF and PDGF for effectively treating
FGF-2 off-target tumors. Nat Commun. 11:37042020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Schlam I, Moges R, Morganti S, Tolaney SM
and Tarantino P: Next-generation antibody-drug conjugates for
breast cancer: Moving beyond HER2 and TROP2. Crit Rev Oncol
Hematol,. 190:1040902023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Shibata N, Cho N, Koyama H and Naito M:
Development of a degrader against oncogenic fusion protein
FGFR3-TACC3. Bioorg Med Chem Lett. 60:1285842022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kato Y, Tabata K, Kimura T,
Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y,
Matsuki M, et al: Lenvatinib plus anti-PD-1 antibody combination
treatment activates CD8+ T cells through reduction of
tumor-associated macrophage and activation of the interferon
pathway. PLoS One. 14:e02125132019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pinkerneil M, Hoffmann MJ, Schulz WA and
Niegisch G: HDACs and HDAC inhibitors in urothelial
carcinoma-perspectives for an antineoplastic treatment. Curr Med
Chem. 24:4151–4165. 2017. View Article : Google Scholar
|
|
121
|
Jaromin M, Konecki T and Kutwin P:
Revolutionizing treatment: Breakthrough approaches for
BCG-unresponsive non-muscle-invasive bladder cancer. Cancers
(Basel). 16:13662024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Yue S, Li Y, Chen X, Wang J, Li M, Chen Y
and Wu D: FGFR-TKI resistance in cancer: Current status and
perspectives. J Hematol Oncol. 14:232021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Facchinetti F, Hollebecque A, Braye F,
Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez
Arango JD, et al: Resistance to selective FGFR inhibitors in
FGFR-Driven urothelial cancer. Cancer Discov. 13:1998–2011. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ruder S, Martinez J, Palmer J, Arham AB
and Tagawa ST: Antibody-drug conjugates in urothelial carcinoma:
Current status and future. Curr Opin Urol. 35:292–300. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ruan R, Li L, Li X, Huang C, Zhang Z,
Zhong H, Zeng S, Shi Q, Xia Y, Zeng Q, et al: Unleashing the
potential of combining FGFR inhibitor and immune checkpoint
blockade for FGF/FGFR signaling in tumor microenvironment. Mol
Cancer. 22:602023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Li R, Linscott J, Catto JWF, Daneshmand S,
Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, et al:
FGFR inhibition in urothelial carcinoma. Eur Urol. 87:110–122.
2025. View Article : Google Scholar
|
|
127
|
Jogo T, Nakamura Y, Shitara K, Bando H,
Yasui H, Esaki T, Terazawa T, Satoh T, Shinozaki E, Nishina T, et
al: Circulating tumor DNA analysis detects FGFR2 Amplification and
concurrent genomic alterations associated with FGFR inhibitor
efficacy in advanced gastric cancer. Clin Cancer Res. 27:5619–5627.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kommalapati A, Tella SH, Borad M, Javle M
and Mahipal A: FGFR inhibitors in oncology: Insight on the
management of toxicities in clinical practice. Cancers (Basel).
13:29682021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Rugo HS: Management of toxicities from
antibody-drug conjugates. Clin Adv Hematol Oncol. 23:96–99.
2025.PubMed/NCBI
|
|
130
|
Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh
M, Nabavi N, Sethi G, Zhao P and Liu P: Advances in cancer
immunotherapy: Historical perspectives, current developments, and
future directions. Mol Cancer. 24:1362025. View Article : Google Scholar : PubMed/NCBI
|
